Evidence map›Paper›PMID 41346473›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Production of

Manon Buscaglia, Bastian Gouriou, Yoann Asquoët, Nelly Le Goïc, Fabienne Le Grand, Mayssa Hachem, Philippe Soudant

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manon BuscagliaUniv Brest, CNRS, IRD, Ifremer, LEMAR, Plouzané, France.
Bastian GouriouUniv Brest, CNRS, IRD, Ifremer, LEMAR, Plouzané, France.
Yoann AsquoëtUniv Brest, CNRS, IRD, Ifremer, LEMAR, Plouzané, France.
Nelly Le GoïcUniv Brest, CNRS, IRD, Ifremer, LEMAR, Plouzané, France.
Fabienne Le GrandUniv Brest, CNRS, IRD, Ifremer, LEMAR, Plouzané, France.
Mayssa HachemDepartment of Chemistry, Khalifa University of Sciences and Technology, Abu Dhabi, United Arab Emirates.
Philippe SoudantUniv Brest, CNRS, IRD, Ifremer, LEMAR, Plouzané, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docosahexaenoic acid (DHA, 22:6n-3) is the predominant polyunsaturated fatty acid in the human brain and eyes, playing a crucial role in vision and cognitive development. DHA deficiency has been associated with ocular diseases, such as macular degeneration and glaucoma, as well as neurodegenerative disorders. Since the human body has a limited ability to synthesize DHA from its precursor, alpha-linolenic acid (ALA, 18:3n-3), targeted DHA supplementation is essential for these patients. To investigate DHA metabolism and integration, researchers commonly use stable (

Indexed as

13C-labeled DHAAurantiochytrium mangroveiCrypthecodinium cohniiomega-3sustainable production

Identifiers

PMID41346473
PMCPMC12672524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.